Literature DB >> 24867836

The setting of a botulinum toxin treatment service.

Maurizio Cavallini1.   

Abstract

The administration of botulinum toxin is an activity performed mostly by a specialist service for the management of a wide range of neurological conditions. For therapeutic purposes botulinum toxin type A is used, although in selected patients who develop antibodies specific for the serotype A botulinum toxin B can be used for the treatment. Hereby, we describe the organizational arrangements for the botulinum toxin treatment service at the Department of Neurology of Hospital Cardinal Massaia based in Asti. The diseases most frequently treated are movement disorders (primary and secondary focal dystonia, blepharospasm, facial emispasmo) spasticity and, more recently, chronic migraine. In particular, the latter application is one of the most promising expansions of the use of this drug in the few past years, although a larger number of patients are required to determine its efficacy and the related tolerability profile.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867836     DOI: 10.1007/s10072-014-1742-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  7 in total

Review 1.  Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission.

Authors:  Frédéric A Meunier; Giampietro Schiavo; Jordi Molgó
Journal:  J Physiol Paris       Date:  2002 Jan-Mar

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Authors:  H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 4.  Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

Authors:  K R Aoki
Journal:  Neurotoxicology       Date:  2005-07-05       Impact factor: 4.294

Review 5.  Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.

Authors:  M F Brin
Journal:  Muscle Nerve Suppl       Date:  1997

6.  OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Authors:  David W Dodick; Catherine C Turkel; Ronald E DeGryse; Sheena K Aurora; Stephen D Silberstein; Richard B Lipton; Hans-Christoph Diener; Mitchell F Brin
Journal:  Headache       Date:  2010-05-07       Impact factor: 5.887

7.  Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.

Authors:  Andrew Blumenfeld; Stephen D Silberstein; David W Dodick; Sheena K Aurora; Catherine C Turkel; William J Binder
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

  7 in total
  1 in total

1.  Anatomical recommendations for safe botulinum toxin injection into temporalis muscle: a simplified reproducible approach.

Authors:  Won-Kang Lee; Jung-Hee Bae; Kyung-Seok Hu; Takafumi Kato; Seong-Taek Kim
Journal:  Surg Radiol Anat       Date:  2016-09-08       Impact factor: 1.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.